$0.53
+0.57%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.55
From 52W high−82.66%
Volume54192.00
Market cap$23.01M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$0.55
From 52W high
−82.66%
Volume
54192.00
Market cap
$23.01M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
30.1
MomentumView details →
1D Return
+0.57%
YTD Return
−65.20%
SummaryUpdated Jun 1, 2026
Estrella Immunopharma, Inc. (NASDAQ:ESLA) is a preclinical-stage biopharmaceutical company founded to develop innovative T-cell therapies for treating blood cancers and solid tumors. Based in Emeryville, California, the company went public in September 2021 and focuses on developing engineered T-cell immunotherapies designed to harness the body's immune system to fight cancer. As a preclinical company, Estrella has not yet generated revenue and remains in the research and development phase of bringing its therapeutic candidates through clinical trials toward potential commercialization.
Similar companies
Latest newsMore news →
Estrella Immunopharma activated University Hospitals Cleveland Medical Center as the fourth clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.40d agoEstrella Immunopharma activated Oregon Health & Science University as the third clinical site for its Phase I/II STARLIGHT-1 trial of EB103 in B-cell non-Hodgkin's lymphoma.48d agoEstrella Immunopharma dosed the first patient in the dose-expansion phase of its STARLIGHT-1 clinical trial for EB103 therapy in advanced B-cell non-Hodgkin's lymphoma.58d ago